| |
Home »
News » 01/06 »
Merck gets FDA approval for anti-vomiting drug
Merck gets FDA approval for anti-vomiting drug
Date published: 12/01/2006
Merck,
parent company of MSD (Merck Sharp & Dohme), has been granted approval from
the US Food and Drug Administration (FDA) for further use of the drug Emend.
Emend is used to stop nausea and vomiting in patients receiving chemotherapy
and the FDA approval allows it to be used in combination with other such drugs,
or antiemetics.
Dr Kelly Pendergrass, clinical investigator and medical
oncologist at the Kansas City Cancer Centre, said: "Patients with cancer are
not only facing a serious illness, they also face the possibility of
distressing side effects such as nausea and vomiting from their chemotherapy,
and breast cancer patients are particularly susceptible to these side effects.
"The good news is that, with this expanded indication, Emend can now be
used with other antiemetics in the wider population of patients receiving
moderately emetogenic chemotherapy to help prevent these worrisome and
challenging side effects before they occur."
The FDA approval was based
on a study that showed the use of Emend with other drugs reduced the chances of
nausea and vomiting during chemotherapy for breast cancer.
© Adfero Ltd
Disclaimer
AllAboutMedicalSales excludes any warranty, express or implied, as to
the quality, accuracy, timeliness, completeness or fitness for a particular
purpose of this briefing. AllAboutMedicalSales will not be liable for any
claims, penalties, losses, damages, costs, or expenses arising from the use of
or inability to use this briefing or from any unauthorised access to or
alteration of the Briefing. AllAboutMedicalSales makes no warranty that the
contents of this briefing are compatible with all computer systems and
browsers.
|
